Euromedis Groupe (ALEMG.PA)
EUR 3.58
(0.28%)
EUR 3.58
(0.28%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.55 Million EUR | 1.78% |
| 2022 | -5.65 Million EUR | -179.62% |
| 2021 | 7.1 Million EUR | -75.83% |
| 2020 | 29.4 Million EUR | 901.53% |
| 2019 | -3.66 Million EUR | -72.06% |
| 2018 | -2.13 Million EUR | -773.67% |
| 2017 | -244 Thousand EUR | -118.89% |
| 2016 | 1.29 Million EUR | -61.41% |
| 2015 | 3.34 Million EUR | -15.28% |
| 2014 | 3.95 Million EUR | 13.4% |
| 2013 | 3.48 Million EUR | 53.73% |
| 2012 | 2.26 Million EUR | 481.65% |
| 2011 | -594 Thousand EUR | -127.77% |
| 2010 | 2.13 Million EUR | 182.55% |
| 2009 | -2.59 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -699 Thousand EUR | 0.0% |
| 2023 Q4 | -194.59 Thousand EUR | 0.0% |
| 2023 Q3 | -194.59 Thousand EUR | 96.59% |
| 2023 Q2 | -5.7 Million EUR | -120.74% |
| 2023 Q1 | -2.58 Million EUR | 61.32% |
| 2023 FY | -5.55 Million EUR | 1.78% |
| 2022 FY | -5.65 Million EUR | -179.62% |
| 2022 Q1 | -2.82 Million EUR | 9.53% |
| 2022 Q2 | -5.9 Million EUR | -109.32% |
| 2022 Q3 | 253.5 Thousand EUR | 104.29% |
| 2022 Q4 | -6.68 Million EUR | -2735.11% |
| 2021 FY | 7.1 Million EUR | -75.83% |
| 2021 Q1 | 3.13 Million EUR | -86.73% |
| 2021 Q2 | 6.41 Million EUR | 104.43% |
| 2021 Q3 | -1.04 Million EUR | -116.23% |
| 2021 Q4 | -3.11 Million EUR | -199.66% |
| 2020 FY | 29.4 Million EUR | 901.53% |
| 2020 Q1 | 2.64 Million EUR | 323.73% |
| 2020 Q2 | 4.99 Million EUR | 89.32% |
| 2020 Q3 | 12.34 Million EUR | 147.01% |
| 2020 Q4 | 23.63 Million EUR | 91.46% |
| 2019 Q3 | -863.5 Thousand EUR | -30.44% |
| 2019 Q4 | -1.18 Million EUR | -36.65% |
| 2019 Q1 | -356 Thousand EUR | 0.0% |
| 2019 FY | -3.66 Million EUR | -72.06% |
| 2019 Q2 | -662 Thousand EUR | -85.96% |
| 2018 FY | -2.13 Million EUR | -773.67% |
| 2017 Q2 | -634.5 Thousand EUR | 0.0% |
| 2017 FY | -244 Thousand EUR | -118.89% |
| 2017 Q4 | -204.5 Thousand EUR | 0.0% |
| 2017 Q3 | -204.5 Thousand EUR | 67.77% |
| 2017 Q1 | -634.5 Thousand EUR | -223.81% |
| 2016 Q2 | 245 Thousand EUR | 0.0% |
| 2016 FY | 1.29 Million EUR | -61.41% |
| 2016 Q4 | 512.49 Thousand EUR | 0.0% |
| 2016 Q1 | 245 Thousand EUR | -38.9% |
| 2016 Q3 | 512.49 Thousand EUR | 109.18% |
| 2015 Q4 | 401 Thousand EUR | 0.0% |
| 2015 Q3 | 401 Thousand EUR | -18.16% |
| 2015 Q2 | 490 Thousand EUR | 0.0% |
| 2015 FY | 3.34 Million EUR | -15.28% |
| 2015 Q1 | 490 Thousand EUR | -22.65% |
| 2014 Q1 | 1.02 Million EUR | 6.51% |
| 2014 Q4 | 633.5 Thousand EUR | 0.0% |
| 2014 Q3 | 633.5 Thousand EUR | -38.07% |
| 2014 FY | 3.95 Million EUR | 13.4% |
| 2014 Q2 | 1.02 Million EUR | 0.0% |
| 2013 Q1 | 1.05 Million EUR | 55.84% |
| 2013 Q3 | 960.5 Thousand EUR | -8.83% |
| 2013 Q4 | 960.5 Thousand EUR | 0.0% |
| 2013 FY | 3.48 Million EUR | 53.73% |
| 2013 Q2 | 1.05 Million EUR | 0.0% |
| 2012 Q4 | 676 Thousand EUR | 0.0% |
| 2012 Q2 | 543.5 Thousand EUR | 0.0% |
| 2012 FY | 2.26 Million EUR | 481.65% |
| 2012 Q1 | 543.5 Thousand EUR | -6.21% |
| 2012 Q3 | 676 Thousand EUR | 24.38% |
| 2011 Q4 | 579.5 Thousand EUR | 0.0% |
| 2011 Q3 | 579.5 Thousand EUR | 0.0% |
| 2011 FY | -594 Thousand EUR | -127.77% |
| 2010 FY | 2.13 Million EUR | 182.55% |
| 2009 FY | -2.59 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Affluent Medical SA | -13.06 Million EUR | 57.468% |
| Bluelinea Société Anonyme | -1.61 Million EUR | -244.597% |
| Carmat SA | -52.51 Million EUR | 89.419% |
| Diagnostic Medical Systems S.A. | -2.26 Million EUR | -145.351% |
| Eurobio Scientific Société anonyme | 10.14 Million EUR | 154.799% |
| Ikonisys S.A. | -2.19 Million EUR | -153.322% |
| Implanet S.A. | -6.15 Million EUR | 9.771% |
| Median Technologies SA | -23 Million EUR | 75.845% |
| SpineGuard SA | -3.97 Million EUR | -39.765% |
| Theraclion SA | -3.15 Million EUR | -76.195% |
| Euroapi S.A. | -234.3 Million EUR | 97.628% |
| Guerbet SA | 38.67 Million EUR | 114.37% |